Ivermectin,

Code: i8898-1g D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Ivermectin has been used:in Caenorhabditis elegans fecundity assayin larval development testto measure in vivo topical acaricide activity of com...


en savoir plus

Votre prix
£105.00 1G
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Ivermectin has been used:in Caenorhabditis elegans fecundity assayin larval development testto measure in vivo topical acaricide activity of compounds in ratsto assess its acute and chronic effects to zebrafishin percutaneous drug injection method to treat cystic echinococcosisin liquid chromatography with fluorescence detection method

Biochem/physiol Actions

Positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptor; also modulates glutamate-GABA-activated chloride channels.

Features and Benefits

This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Ivermectin is a macro-cyclic lactone, derived from avermectin. It functions as an antiparasitic agent. Ivermectin is used against gastrointestinal roundworms, lungworms, mites and lice. It is used to treat onchocerciasis, strongyloidiasis, ascariasis and filariases.

Other Notes

Primarily ivermectin B1a.

Packaging

1 g in poly bottle

250 mg in poly bottle

antibiotic activity spectrumparasites
application(s)agricultureenvironmental
formpowder
Gene Informationhuman ... ABCB1(5243), CYP3A4(1576)mouse ... Abcb1a(18671), Abcb1b(18669)
InChI keyAZSNMRSAGSSBNP-XPNPUAGNSA-N
InChI1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
mode of actioncell membrane | interferes
originatorMerck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level100
SMILES string[H][C@@]1(O[C@]2(CC[C@@H]1C)C[C@@H]3C[C@@H](CC=C(C)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)C=CC=C6/CO[C@]7([H])[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]67O)O2)[C@@H](C)CC
solubilityMEK: 50 mg/mL
storage temp.2-8°C
Code
Description
Unité de vente
Prix annoncé
Qté
I8898-250MG
Ivermectin,

Unité:250MG
Prix annoncé: £34.90
Source:Prix annoncé
AJOUTER
Cas Number70288-86-7
Hazard Class6.1
Un Number2811
Pack GroupII
Ce produit répond aux critères suivants: